Overview
- The new platform connects employers to more than 15 independent administrators—such as GoodRx, Mark Cuban's Cost Plus Drug Company, Teladoc Health and Transcarent—that deliver services at the same medicine price while competing on administration and care support.
- Employers can purchase a multi-dose form of Zepbound at a net price of $449 per month across all doses with no rebates, providing clearer cost visibility.
- Companies choose how much of the cash price to subsidize, for example $50 to $100 per month, with employees paying the balance.
- Lilly says the model targets employer concerns over price transparency and benefits flexibility as coverage for GLP-1 weight-loss drugs remains uneven, with surveys showing limited adoption across large firms.
- Lilly expects some employers to add coverage in the coming months and others in 2027, and Medicare is slated to begin covering GLP-1 obesity medicines later this year under recent agreements.